1IY0.F Monopar Therapeutics Inc.
- Market cap
- EUR 428M
- P/E
- -
- P/B
- 3.61x
- ROE
- -14.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1IY0.F undervalued?
Graham numberThe Graham number of Monopar Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Monopar Therapeutics Inc. fundamental analysis
No fundamental analysis for Monopar Therapeutics Inc. yet.
Monopar Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase…
Full company profileMonopar Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Monopar Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.13M | -10.5M | -8.83M | -16.2M | -16.7M | -23.7M |
| EBITDA | - | -10.5M | -8.83M | -16.2M | -16.7M | -23.7M |
| Net Income | -9.10M | -10.5M | -8.40M | -15.6M | -13.7M | -18.4M |
| EPS | -3.61 | -4.06 | -2.82 | -2.55 | -2.05 | -2.74 |
| Balance Sheet | ||||||
| Total Assets | 20.5M | 13.2M | 7.35M | 60.3M | 141M | 135M |
| Total Liabilities | 1.58M | 3.14M | 1.76M | 5.25M | 2.89M | 4.12M |
| Shareholders' Equity | 18.9M | 10.1M | 5.59M | 55.0M | 138M | 131M |
| Cash & Short-term Investments | 20.3M | 8.19M | 7.27M | 45.8M | 61.8M | 52.8M |
| Cash Flow | ||||||
| Operating Cash Flow | -7.32M | -7.23M | -7.86M | -6.40M | -12.2M | -13.4M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -7.32M | -7.23M | -7.86M | -6.40M | -12.2M | -13.4M |
| Ratios | ||||||
| ROE | -48.1% | -104.2% | -150.4% | -28.3% | -10.0% | -14.1% |
| ROA | -44.4% | -79.5% | -114.4% | -25.9% | -9.7% | -13.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Monopar Therapeutics Inc. dividends
Monopar Therapeutics Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:5 on Aug 13, 2024.
Who owns Monopar Therapeutics Inc.
- Insiders 23.46%
- Institutions 76.54%
- Public & others 0.00%
- Shares outstanding 6.71M
- Free float 4.47M
Monopar Therapeutics Inc. company profile
- Company name
- Monopar Therapeutics Inc.
- Ticker
- 1IY0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Fiscal year end
- December
- Address
- 1000 Skokie Boulevard, Wilmette, IL, United States, 60091
- Phone
- 847 388 0349
- Website
- monopartx.com
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. management
7- Dr. Christopher M. Starr Ph.D.Co-Founder & Independent Executive Chairman of the Board · born 1952
- Dr. Chandler D. Robinson M.B.A., M.D., M.Sc.Co-Founder, CEO, President & Director · born 1984
- Mr. Quan Anh VuCFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer · born 1972
- Mr. Andrew J. Cittadine M.B.A.Chief Operating Officer · born 1972
- Dr. Patrice P. Rioux M.D., Ph.D.Acting Chief Medical Officer · born 1951
- Ms. Susan RodriguezChief Commercial & Strategy Officer · born 1962
- Dr. Jeffrey D. Kent FACG, FACP, M.D.Executive Vice President of Head of Medical Affairs · born 1962